KOSDAQBiotech & Pharma323990

Vaxcell-Bio Therapeutics

₩4,290▼ 0.46%2026-10-02 close

Market Cap

₩99.7B

Turnover

₩200M

Volume

50,000 shares

Shares out.

23.3M

PER

—

PBR

2.0×

EPS

-₩643

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Vaxcell-Bio Eyes Path to Liver Cancer Cell Therapy

Vaxcell-Bio, having completed Phase 2a for its NK-cell liver cancer therapy Vax-NK/HCC, is re-pursuing an advanced regenerative medicine treatment pathway even as its losses continue to widen despite revenue growth.

1
Following completion of Phase 2a for liver cancer therapy Vax-NK/HCC (VCB-1102), the company is re-filing for advanced regenerative medicine treatment status after supplementing data
2
2025 consolidated revenue surged to KRW 7.06 billion year-on-year, but operating loss reached KRW 15.50 billion and owners' net loss KRW 13.34 billion, both widening
3
Quarterly operating loss has widened from KRW 4.10 billion in Q2 2025 to KRW 5.02 billion in Q2 2026
4
The company has built parallel cash-generating operations through internalized pharmaceutical distribution (former SH Pharm) and the companion-animal cancer drug Baxleukin-15
5
The company continues to diversify its follow-on pipeline including CAR-MIL, dual-target CAR-T, and small-molecule/bispecific drug candidates

Business structure

Founded in 2010 and listed on KOSDAQ in 2020, Vaxcell-Bio is a cancer immunotherapy specialist that operates cell and gene therapies (NK cells, CAR-T, CAR-NK) alongside small-molecule targeted oncology drugs, bispecific antibody candidates, companion-animal healthcare, and pharmaceutical distribution.

Its core pipeline asset is the autologous NK-cell therapy Vax-NK/HCC (VCB-1102), developed in combination with hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma; the company has completed Phase 2a and submitted the final clinical study report to the Ministry of Food and Drug Safety.

Beyond this, the company is diversifying into a next-generation CAR-T for multiple myeloma called CAR-MIL (VCB-1201), a dual-target CAR-T for solid tumors targeting EphA2 and PD-L1 (VCB-1204), a CAR-NK candidate for autoimmune disease, a first-in-class MYO1D-degrader small-molecule oncology drug (VBC-1301), a nanobody-based bispecific antibody (VBC-1501), and an eye-drop formulation for macular degeneration (VBC-1502).

Small-cell lung cancer and pancreatic cancer indications are being pursued through the advanced regenerative medicine clinical research framework.

To diversify its revenue base, the company internalized pharmaceutical distribution by acquiring former SH Pharm, establishing a structure capable of meeting KOSDAQ's minimum annual revenue requirement of KRW 3 billion for continued listing.

Its prescription companion-animal cancer drug Baxleukin-15 is sold through Yuhan Corporation, and the immune-support supplement Goldmune has been supplied to Medivet and VisionMed to expand domestic and overseas sales.

In the domestic cell-therapy competitive landscape, other NK-cell-based companies are running trials in different solid-tumor indications such as gastric, lung and colorectal cancer, or pancreatic and breast cancer, or glioblastoma and cholangiocarcinoma, resulting in indication-specific rather than head-to-head competition.

Overall, the business model pairs cell and gene therapy R&D with cash-generating operations in companion-animal healthcare and pharmaceutical distribution to help self-fund research spending.

Earnings trend

Quarterly revenue · Operating profit

₩2B-₩4.1B25Q2₩1.7B-₩3.4B25Q3₩1.7B-₩3.6B25Q4₩1.5B-₩4.6B26Q1₩1.6B-₩5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

-₩8.2B2022₩13,723,327-₩11.5B2023₩1.9B-₩15B2024₩7.1B-₩15.5B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩2B	-₩4.1B	−206.7%
2025Q3	₩1.7B	-₩3.4B	−208.1%
2025Q4	₩1.7B	-₩3.6B	−214.9%
2026Q1	₩1.5B	-₩4.6B	−301.2%
2026Q2	₩1.6B	-₩5B	−309.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	—	-₩8.2B	-₩6.8B	—	−29.3%	3.6%
2023	₩13,723,327	-₩11.5B	-₩10.3B	−83851.2%	−12.3%	1.8%
2024	₩1.9B	-₩15B	-₩10.6B	−791.9%	−14.8%	6.9%
2025	₩7.1B	-₩15.5B	-₩13.3B	−219.6%	−21.8%	9.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Consolidated revenue in 2025 rose sharply to KRW 7.06 billion from KRW 1.90 billion in 2024, a marked jump when compared with the essentially negligible KRW 14 million recorded in 2023, reflecting the effect of internalizing the distribution business.

Despite the revenue increase, operating loss continued to widen, reaching KRW 15.50 billion in 2025 versus KRW 15.04 billion in 2024, KRW 11.51 billion in 2023, and KRW 8.21 billion in 2022.

The extreme -83,851.2% operating margin recorded in 2023 reflects the fact that the company had virtually no revenue at that early clinical-stage point, so the absolute loss trend is the more meaningful figure.

Net loss attributable to owners expanded from KRW 6.83 billion in 2022 to KRW 10.27 billion in 2023, KRW 10.62 billion in 2024, and KRW 13.34 billion in 2025.

On a quarterly basis, revenue held in a narrow range, moving from KRW 1.99 billion in Q2 2025 to KRW 1.62 billion in Q2 2026 without a clear directional trend, while operating loss eased briefly from KRW 4.10 billion in Q2 2025 to KRW 3.44 billion in Q3 2025 before widening again to KRW 3.65 billion in Q4 2025, KRW 4.62 billion in Q1 2026, and KRW 5.02 billion in Q2 2026.

Owners' net loss over the same quarters was KRW 3.82 billion, KRW 2.68 billion, KRW 4.22 billion, KRW 3.97 billion, and KRW 4.05 billion, showing considerable quarter-to-quarter volatility.

This sustained loss pattern has eroded owners' equity, which fell from KRW 23.33 billion in 2022 (following a jump to KRW 83.49 billion in 2023) to KRW 71.99 billion in 2024 and KRW 61.13 billion in 2025, while operating cash flow remained negative every year from 2022 through 2025, in a range of roughly KRW 6.0 to 10.7 billion in annual outflow, underscoring continued reliance on external financing to fund R&D. The debt ratio remained low at 9.4% in 2025, indicating limited balance-sheet leverage risk.

Industry analysis

South Korea's cell and gene therapy industry remains in an active clinical-development phase across NK-cell and CAR-T platforms, with few commercialized solid-tumor products to date, meaning companies are still in an early stage of building clinical evidence across differing indications.

Domestic competitors include NK-cell therapies in Phase 2 targeting gastric, lung and colorectal cancer, others in Phase 1 targeting pancreatic and breast cancer, and separate autologous NK-cell programs in glioblastoma and cholangiocarcinoma, splitting competitive focus by indication.

At the industry level, regulatory reform under the revised advanced regenerative medicine law is acting as a cycle inflection point.

From January 2026, the Ministry of Health and Welfare applied revised guidelines that clarified criteria for intractable diseases and eased non-clinical data submission burdens for low- and medium-risk research, while planning to expand a project-based regulatory sandbox that would allow overseas clinical trial or research results, or domestic research predating the law, to be used in treatment-plan reviews.

In April 2026, the first treatment-plan approval under this system was granted fourteen months after the framework's launch—the first case applying a sandbox exception that allows commercial clinical trial results to satisfy the treatment-plan filing requirement—which industry observers viewed as an environment that could favor companies with global-grade clinical data in accelerating domestic treatment access.

This regulatory shift opens a pathway to accumulate real patient treatment data even ahead of formal drug approval, potentially serving as a pre-commercialization entry route for companies such as Vaxcell-Bio that have completed late-stage trials.

That said, treatment-plan reviews are still handled case by case in consultation with regulators, and as filing volumes rise, review timelines and outcome uncertainty persist as well.

Outlook

Vaxcell-Bio is pursuing a dual-track strategy for its liver cancer therapy VCB-1102 (Vax-NK), weighing entry into a Phase 2b trial against filing for an advanced regenerative medicine treatment plan, with a company representative stating that the treatment-plan route is being pursued first given its relative time and cost efficiency.

Having submitted the Phase 2a final clinical study report and initially pursued treatment-plan conversion, the company recently decided to re-file after supplementing data requested by regulators, and it has stated that it is difficult to provide a specific target timeline for approval.

In this process, joint NK-cell mass-expansion research conducted with a University of Ottawa team achieved cell expansion of over 100,000-fold, a result that could reinforce the case for re-filing if it can be translated into a clinical-grade manufacturing process, quality reproducibility, and application at a new manufacturing site.

The company built its Advanced immunotherapy Open industrialization Platform (A-TOP) facility in 2024 and secured an advanced biopharmaceutical manufacturing license in 2025, and has been transitioning its production system toward the A-TOP NK manufacturing site as its earlier Vax-NK facility wound down operations.

In small-cell lung cancer and pancreatic cancer, the company has submitted a research report and is conducting advanced regenerative medicine clinical research, respectively, including an approved advanced regenerative medicine study for advanced pancreatic cancer at Hwasun Chonnam National University Hospital where VCB-1102 was provided as the treatment.

CAR-MIL for multiple myeloma and the dual-target CAR-T candidate VCB-1204 for solid tumors have been presented as planned to enter Phase 1 through domestic IND filings while pursuing global licensing negotiations in parallel.

The company maintains that it does not view the advanced regenerative medicine pathway as its sole route and will continue to weigh clinical development alongside it, meaning the eventual commercialization path and timing may shift depending on the outcome of discussions with regulators.

Valuation

PER

—

PBR

2.0×

ROE

-24.6%

EPS

-₩643

BPS

₩2,304

Dividend per share

₩0

Vaxcell-Bio remains a clinical- and approval-stage company without meaningful commercial revenue, and its persistent net-loss structure makes conventional earnings-based valuation metrics difficult to apply.

Its price-to-book ratio, set against a backdrop of shrinking owners' equity each year, varies somewhat depending on the calculation basis, and the shares have traded in a range that reflects a premium over net asset value. The company pays no dividend, so dividend-related metrics carry little relevance.

Company value is largely driven by non-financial events—whether and when the advanced regenerative medicine treatment-plan conversion is approved, and how the follow-on pipeline progresses clinically—and the basis for market assessment could shift materially depending on these outcomes.

At this stage, the outcome of pipeline events, rather than any directional improvement in financial results, appears to be the central focus of valuation discussions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Phase 2a Efficacy Data Secured in Liver Cancer

Independent review committee analysis confirmed an objective response rate of 68.75% and disease control rate of 100% for the Vax-NK/HCC plus HAIC combination, with time to tumor progression reported at 16.82 months or more.

This compares favorably with existing standard-of-care outcomes, and the company submitted the final study report to the drug regulator on this basis. Such late-stage clinical data could serve as supporting evidence for advanced regenerative medicine treatment conversion or future licensing negotiations.

Regulatory Easing Opens a Treatment-Market Entry Path

The Ministry of Health and Welfare has been restructuring the advanced regenerative medicine framework through 2026 guideline revisions and an expanded project-based regulatory sandbox, aiming to allow patient treatment via treatment-plan review even ahead of formal drug approval.

In April 2026, the first approval of a treatment plan based on commercial clinical trial results confirmed the practical viability of this route. Analysts have noted that Vaxcell-Bio, having completed late-stage clinical work on its pipeline, could be positioned to benefit from this regulatory shift.

Diversified Cash Generation via Distribution and Pet Health Businesses

Through internalizing pharmaceutical distribution via the SH Pharm acquisition and selling the companion-animal cancer drug Baxleukin-15 through Yuhan Corporation, the company has secured revenue sources outside of new drug development.

This helped drive a large year-on-year increase in 2025 consolidated revenue and established a structure capable of meeting KOSDAQ's minimum listing revenue requirement. Maintaining a baseline revenue stream, independent of pipeline clinical and regulatory risk, could serve as a financial buffer.

Bear factors

Widening Operating Losses and Shrinking Equity

Quarterly operating loss widened from KRW 4.10 billion in Q2 2025 to KRW 5.02 billion in Q2 2026, and annual operating loss also grew every year, from KRW 8.21 billion in 2022 to KRW 15.50 billion in 2025. As a result, owners' equity has trended down from KRW 83.49 billion in 2023 to KRW 61.13 billion in 2025.

With loss size expanding alongside revenue growth, both cost control and the need for additional financing are becoming more pronounced.

Uncertain Timing for the Commercialization Pathway

The company has re-filed for advanced regenerative medicine treatment conversion after data supplementation, and it maintains that it cannot provide a specific target timeline for approval. Whether to pursue a Phase 2b trial also remains at the review stage rather than being finalized. This makes it difficult to gauge the timing of eventual commercialization.

Intensifying Domestic Cell-Therapy Competition on a Small Revenue Base

Domestically, multiple companies are running separate clinical programs using NK-cell platforms across a range of solid tumors, including gastric, lung and colorectal cancer, pancreatic and breast cancer, and glioblastoma and cholangiocarcinoma, sustaining indication-by-indication competition.

In contrast, Vaxcell-Bio's 2025 consolidated revenue stood at only KRW 7.06 billion, still a modest base. Funding new drug development will require both an expanded revenue base and tangible pipeline progress in parallel.

Risk factors

Regulatory and Approval Risk

The approval and timing of the re-filed advanced regenerative medicine treatment plan remain unconfirmed, and the company itself has stated it is difficult to provide a specific timeline. If additional data requirements emerge during further regulatory consultation, further delays are possible.

Should the company pivot to a formal approval pathway such as a Phase 2b trial, that would require separate time and cost.

Financial and Funding Risk

Operating cash flow has been negative every year from 2022 through 2025, in a range of roughly KRW 6.0 to 10.7 billion in annual outflow, indicating heavy reliance on external financing to sustain R&D. Owners' equity has also trended lower as losses accumulate.

Any additional rights offering or convertible bond issuance would carry potential dilution risk for existing shareholders.

Competitive and Technology-Validation Risk

Whether the NK-cell mass-expansion technology co-developed with the University of Ottawa can be translated into an actual clinical-grade manufacturing process, quality reproducibility, and application at a new facility remains to be validated.

Competition in CAR-T, CAR-NK, and NK-cell therapy development continues both domestically and globally, creating ongoing pressure to demonstrate technical differentiation. While pipeline diversification is underway, most candidates remain at the preclinical or early clinical stage.

What to watch next

November 2026
The Q3 quarterly report filing will show whether revenue, operating loss, and cash flow continue the loss-widening trend seen in the prior quarter (Q2 2026).
H2 2026 (timing unconfirmed)
Regulators' review outcome on the re-filed advanced regenerative medicine treatment plan needs to be tracked. The company has not disclosed a specific approval timeline, so confirmation via disclosure or IR updates will be necessary.
H2 2026
Whether the NK-cell mass-expansion technology is applied to the actual clinical manufacturing process (the A-TOP NK facility) and whether related quality-reproducibility data is disclosed should be monitored.
H2 2026
Progress on domestic Investigational New Drug (IND) filings for CAR-MIL (VCB-1201) and the dual-target CAR-T candidate (VCB-1204) should be checked.

Overall view

Vaxcell-Bio has secured Phase 2a efficacy data for its NK-cell liver cancer therapy Vax-NK/HCC and is re-pursuing entry into the pre-approval treatment market amid the government's regulatory easing under the advanced regenerative medicine framework.

At the same time, it has broadened its revenue base through internalized pharmaceutical distribution and companion-animal cancer drug sales, driving a large year-on-year jump in 2025 consolidated revenue.

Yet apart from that revenue growth, both operating loss and net loss have expanded every year, the loss-widening trend has continued in recent quarters, and owners' equity has been on a declining trajectory.

The advanced regenerative medicine treatment conversion is currently at the re-filing stage after data supplementation, and the company itself has not been able to provide a specific approval timeline, leaving uncertainty around both the commercialization path and its timing.

Follow-on pipeline assets such as CAR-MIL and the dual-target CAR-T remain at an early development stage, meaning medium- to long-term diversification will hinge on further clinical data.

Ahead of any investment decision, it would be worth monitoring the regulatory review outcome, quarterly loss trends, and the company's financing plans.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.